{"Clinical Trial ID": "NCT01572727", "Intervention": ["INTERVENTION 1:", "BKM120 and Paclitaxel", "In adult women receiving a more paclitaxel study drug whose histology has been confirmed, inoperative, locally advanced, or metastatic HER2-C.-B.", "INTERVENTION 2:", "Placebo and Paclitaxel", "In adult women with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received placebo plus paclitaxel"], "Eligibility": ["Incorporation criteria:", "Locally advanced or metastatic breast cancer", "HER2 negative disease, and known hormonal receptor status - ER/PgR (common breast cancer classification tests)", "A tumour sample should be sent to a central laboratory for the identification of biomarkers (PI3K activation status) prior to randomization", "Adequate function of bone marrow and organs", "A measurable or non-measurable disease", "- Exclusion criteria:", "Prior chemotherapy for a locally advanced or metastatic disease", "Previous treatment with PI3K or AKT inhibitors", "The patient has symptomatic CNS metastases", "\u2022 Concurrent malignance or malignancy within 3 years of enrolment in the study", "Growth or radiation factors stimulating haematopoietic colonies within 2 to 4 weeks prior to the start of the study", "\u2022 Chronic increase or treatment (> 5 days) with corticosteroids or other immunosuppressant", "Active heart disease (cardiac) as defined in the protocol", "Hypersensitivity or known contraindications to the use of paclitaxel", "Pregnant or lactating women", "Some scores on an anxious and depressed mood questionnaire given to the screening", "Other criteria defined by the Protocol may apply."], "Results": ["Performance measures:", "\u00b7 Evaluation of progression-free survival (PFS) by the local investigator (phase ll)", "The progression was defined using the criteria for assessing response in solid tumour criteria (RECIST v1.1), such as a 20% increase in the sum of the longest diameter of the target lesions, or a measurable increase in non-target injury, or the occurrence of new lesions.", "Timeline: Every 8 weeks from randomization to disease progression up to 10 months after futility analysis", "Results 1:", "Title of arm/group: BKM120 and Paclitaxel", "- Arm/group description: Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received a more paclitaxel study drug", "Total number of participants analysed: 168", "Median (95% confidence interval)", "Unit of measurement: Month 8.0 (7.2 to 9.2)", "Results 2:", "Title of the arm/group: Placebo and Paclitaxel", "Description of the arm/group: Adult females with histologically confirmed, inoperative, locally advanced or metastatic HER2- BC who received placebo plus paclitaxel", "Total number of participants analysed: 170", "Median (95% confidence interval)", "Unit of measure: Month 9.2 (7.3 to 11.0)"], "Adverse Events": ["Undesirable Events 1:", "Total: 61/202 (30.20 per cent)", "NEUTROPENIAL FEBRILE 1/202 (0.50%)", "LEUKOPENIA 0/202 (0.00 %)", "NEUTROPENIA 2/202 (0.99%)", "- CARDIAC SHORT FILTER 0/202 (0.00 %)", "CARDIO 1/202 (0.50%) RESPIRATORY JUDGMENT", "PERI-CARDIAL EFFICIENCY 1/202 (0.50%)", "- CATARACT 1/202 (0.50%)", "OPTICAL NEUROPATHY 0/202 (0.00 %)", "- ABDOMINAL PEACE 0/202 (0.00 %)", "CONSTIPATION 0/202 (0.00 %)", "DIARRHOEA 5/202 (2.48%)", "Adverse Events 2:", "Total: 42/201 (20.90 per cent)", "NEUTROPENIA FEBRILE 0/201 (0.00 %)", "LUKOPENIA 1/201 (0.50%)", "NEUTROPENIA 0/201 (0.00 %)", "- CARDIAC FEATURED FILTER 1/201 (0.50%)", "- CARDIO RESPIRATORY JUDGMENT 0/201 (0.00 %)", "PERIOD EFFICIENCY 0/201 (0.00 %)", "- CATARACT 1/201 (0.50%)", "OPTICAL NEUROPATHY 1/201 (0.50%)", "- ABDOMINAL PEACE 1/201 (0.50%)", "CONSTIPATION 1/201 (0.50%)", "DIARRHOEA 3/201 (1.49%)"]}